Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883586 | 0.75 | NPY5R (0.39) | HTR2BCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL2524321 | 0.74 | PRMT5 (0.51) | CETPCYP1A2CYP3A4ALOX15ALDH1A1 | |
| SCHEMBL1292908 | 0.72 | ADORA3 (0.53) | ALDH1A1 | |
| SCHEMBL2507996 | 0.72 | HTR3A (0.49) | HTR3AHTR1AHTR2CCYP1A2CYP3A4 | |
| SCHEMBL4495776 | 0.72 | HTR3A (0.60) | HTR3AHTR1AHTR2CALDH1A1HTR2A | |
| SCHEMBL28111704 | 0.71 | CYP1A2 (0.52) | CETPHTR6GBA1CYP1A2CYP3A4 | |
| SCHEMBL9119522 | 0.71 | CDK5 (0.46) | ALDH1A1 | |
| SCHEMBL2885131 | 0.71 | HPGDS (0.41) | HTR2CCYP1A2CYP3A4CYP2D6HPGD | |
| SCHEMBL19124978 | 0.70 | CETP (0.56) | HTR3ACETPHTR1AHTR7HTR6 | |
| SCHEMBL531762 | 0.69 | HTR3A (1.00) | HTR3AHTR1AHTR7HTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552921-B1 | PURINE COMPOUNDS | LILLY CO ELI (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8759360-B2 | Purine compounds | ELI LILLY AND COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2552916-B1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | LILLY CO ELI (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8710063-B2 | Purine compounds used as CB2 agonists | ELI LILLY AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2552921-A1 | PURINE COMPOUNDS | Eli Lilly and Company (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552916-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | Eli Lilly and Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011123372-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123482-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245255-A1 | PURINE COMPOUNDS | ELI LILLY AND COMPANY | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | CNR2, CNR1, P2RX7 | HTR3A 98/4885CETP 2211/4885HTR1A 57/4885 |
| US-20110245255-A1 | PURINE COMPOUNDS | P2RX1, P2RX3, P2RX7 | HTR3A 326/4885CETP 2941/4885HTR1A 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.